Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim S, Nurieva R, Lazar A, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks J, Awiwi M, Elsayes K, Soto L, Melendez B, Davies M, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison J, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022, 40: 509-523.e6. PMID: 35537412, PMCID: PMC9221568, DOI: 10.1016/j.ccell.2022.04.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsColitisHumansImmunologic FactorsImmunotherapyInterleukin-6MiceMyeloid CellsNeoplasmsConceptsImmune checkpoint blockadeExperimental autoimmune encephalomyelitisInterleukin-6 blockadeInterleukin-6Anti-cytotoxic T-lymphocyte-associated antigen 4T-lymphocyte-associated antigen 4Anti-programmed death-1Experimental autoimmune encephalomyelitis symptomsImmune-related adverse eventsICB-treated patientsPromote tumor immunityAnti-CTLA-4Anti-PD-1Improve tumor controlEffector T cellsT helper 1T helper 17Expression of interleukin-6Chemotactic markersImmunotherapy toxicityReduced Th17Antitumor immunityCheckpoint blockadeTumor controlDeath-1